NO963064D0 - Behandling av normotensive glaukoma med angiotensin-II-antagonister - Google Patents

Behandling av normotensive glaukoma med angiotensin-II-antagonister

Info

Publication number
NO963064D0
NO963064D0 NO963064A NO963064A NO963064D0 NO 963064 D0 NO963064 D0 NO 963064D0 NO 963064 A NO963064 A NO 963064A NO 963064 A NO963064 A NO 963064A NO 963064 D0 NO963064 D0 NO 963064D0
Authority
NO
Norway
Prior art keywords
pct
treatment
angiotensin
antagonists
sec
Prior art date
Application number
NO963064A
Other languages
English (en)
Norwegian (no)
Other versions
NO963064L (no
Inventor
Alicia Huxley
Georg Mathis
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO963064L publication Critical patent/NO963064L/no
Publication of NO963064D0 publication Critical patent/NO963064D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO963064A 1994-02-08 1996-07-23 Behandling av normotensive glaukoma med angiotensin-II-antagonister NO963064D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810071 1994-02-08
PCT/IB1995/000056 WO1995021609A1 (en) 1994-02-08 1995-01-26 Treatment of normotensive glaucoma with angiotensin ii antagonists

Publications (2)

Publication Number Publication Date
NO963064L NO963064L (no) 1996-07-23
NO963064D0 true NO963064D0 (no) 1996-07-23

Family

ID=8218203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963064A NO963064D0 (no) 1994-02-08 1996-07-23 Behandling av normotensive glaukoma med angiotensin-II-antagonister

Country Status (17)

Country Link
US (1) US5889020A (de)
EP (1) EP0743852B1 (de)
JP (1) JPH09508641A (de)
CN (1) CN1140409A (de)
AT (1) ATE300287T1 (de)
AU (1) AU1423795A (de)
CA (1) CA2181461A1 (de)
CY (1) CY2567B1 (de)
DE (1) DE69534339T2 (de)
DK (1) DK0743852T3 (de)
ES (1) ES2243933T3 (de)
FI (1) FI963083L (de)
IL (1) IL112520A0 (de)
MX (1) MX9603259A (de)
NO (1) NO963064D0 (de)
WO (1) WO1995021609A1 (de)
ZA (1) ZA95958B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ284395B6 (cs) * 1994-03-16 1998-11-11 Sankyo Company Limited Prostředek pro snižování očního tlaku
JPH10167961A (ja) * 1996-12-11 1998-06-23 Santen Pharmaceut Co Ltd 緑内障治療剤
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
ATE289204T1 (de) * 1999-04-28 2005-03-15 Takeda Pharmaceutical Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
ATE295721T1 (de) * 1999-06-11 2005-06-15 Sankyo Co Den augendruck senkende zusammensetzung zur topischen anwendung
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
AU7954900A (en) * 1999-10-25 2001-05-08 Senju Pharmaceutical Co., Ltd. Tension-relieving agents for ciliary muscle
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
WO2001060362A1 (fr) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. INHIBITEURS DE TNF-$g(a)
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR101087519B1 (ko) * 2003-04-15 2011-11-28 상꾜 가부시키가이샤 안구 내 혈관 신생성 질환의 예방 또는 치료를 위한 의약
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
PL1872783T3 (pl) * 2005-04-21 2012-05-31 Santen Pharmaceutical Co Ltd Środek leczniczy w schorzeniach rogówkowo-spojówkowych
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
HRP20151440T1 (hr) * 2008-12-29 2016-01-29 Trevena, Inc. Efektori beta-arestina i sastavi i metode u kojima se koriste
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
US9518086B2 (en) 2014-02-07 2016-12-13 Trevena, Inc. Crystalline and amorphous forms of a β-arrestin effector
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors
CN105188250A (zh) * 2015-09-09 2015-12-23 上海联影医疗科技有限公司 靶组件以及具有该靶组件的直线加速器
CN105244434B (zh) * 2015-10-13 2017-10-10 北京科技大学 一种C掺杂ZnO热电材料的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03223281A (ja) * 1989-12-01 1991-10-02 Glaxo Group Ltd ベンゾチオフェン誘導体
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
EP0743852B1 (de) 2005-07-27
DE69534339T2 (de) 2006-05-24
DE69534339D1 (de) 2005-09-01
AU1423795A (en) 1995-08-29
US5889020A (en) 1999-03-30
DK0743852T3 (da) 2005-10-17
JPH09508641A (ja) 1997-09-02
ES2243933T3 (es) 2005-12-01
NO963064L (no) 1996-07-23
FI963083A0 (fi) 1996-08-05
WO1995021609A1 (en) 1995-08-17
ATE300287T1 (de) 2005-08-15
FI963083A7 (fi) 1996-08-07
IL112520A0 (en) 1995-05-26
MX9603259A (es) 1997-03-29
ZA95958B (en) 1995-08-08
EP0743852A1 (de) 1996-11-27
FI963083L (fi) 1996-08-07
CA2181461A1 (en) 1995-08-17
CN1140409A (zh) 1997-01-15
CY2567B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
NO963064D0 (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
EP0664792A4 (de) Fibrinogenrezeptor-antagonisten.
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
WO1999024051A3 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
BR9809071A (pt) Agentes farmacológicos
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
DK0711283T3 (da) Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
ATE169019T1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
SE9302218D0 (sv) New use
SE9404438D0 (sv) New process
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi